Cardiovascular Program ICCC, Institut de Recerca Hospital Santa Creu i Sant Pau-IIB Sant Pau, Barcelona, Spain; Endocrinology and Nutrition Department, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Cardiovascular Program ICCC, Institut de Recerca Hospital Santa Creu i Sant Pau-IIB Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Transl Res. 2021 Sep;235:1-14. doi: 10.1016/j.trsl.2021.04.003. Epub 2021 Apr 20.
The molecular understanding of the pathophysiological changes elicited by diabetes in platelets may help in further elucidating the involvement of this pseudo-cell in the increased risk of developing cardiovascular disease and thrombosis in diabetic subjects. We aimed to investigate the differential characteristics of platelets from diabetic patients and nondiabetic controls to unveil the molecular mechanisms behind the increased platelet reactivity in diabetes. We compared platelets from diabetic and control subjects by 2 dimensional-electrophoresis followed by mass spectrometry. Changes in selected differential proteins were validated by immunoprecipitation assays and western blot. Platelet aggregation was measured by light transmittance aggregometry induced by collagen and ADP, and dynamic coagulation analysis of whole blood was measured by thromboelastometry. We observed significant differences in proteins related to platelet aggregation, cell migration, and cell homeostasis. Subjects with diabetes showed higher platelet aggregation and thrombogenicity and higher contents of the stress-related protein complex HSPA8/Hsp90/CSK2α than nondiabetic subjects. Changes in the chaperones HSPA8 and Hsp90, and in CSK2α protein contents correlated with changes in platelet aggregation and blood coagulation activity. In conclusion, the complex HSPA8/Hsp90/CSK2α is involved in diabetes-related platelet hyperreactivity. The role of the HSPA8/Hsp90/CSK2α complex may become a molecular target for the development of future preventive and therapeutic strategies for platelet dysfunction associated with diabetes and its complications.
糖尿病引起血小板病理生理变化的分子机制研究,可能有助于进一步阐明这种伪细胞在糖尿病患者发生心血管疾病和血栓风险增加中的作用。我们旨在通过二维电泳结合质谱技术比较糖尿病患者和非糖尿病对照者血小板的差异特征,揭示糖尿病患者血小板反应性增加的分子机制。我们通过胶原和 ADP 诱导的光透射聚集测定和全血动态凝血分析,测量血小板聚集,并用免疫沉淀测定和 Western blot 验证选定的差异蛋白的变化。我们观察到与血小板聚集、细胞迁移和细胞内稳态相关的蛋白质存在显著差异。与非糖尿病患者相比,糖尿病患者的血小板聚集和血栓形成能力更高,应激相关蛋白复合物 HSPA8/Hsp90/CSK2α 的含量也更高。热休克蛋白 A8(HSPA8)和热休克蛋白 90(Hsp90)的变化以及 CSK2α 蛋白含量的变化与血小板聚集和血液凝固活性的变化相关。总之,HSPA8/Hsp90/CSK2α 复合物参与了糖尿病相关的血小板高反应性。HSPA8/Hsp90/CSK2α 复合物的作用可能成为与糖尿病及其并发症相关的血小板功能障碍的未来预防和治疗策略的分子靶点。